BGLC
Income statement / Annual
Last year (2023), BioNexus Gene Lab Corp.'s total revenue was $9.77 M,
a decrease of 10.60% from the previous year.
In 2023, BioNexus Gene Lab Corp.'s net income was -$2.63 M.
See BioNexus Gene Lab Corp.,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
Operating Revenue |
$9.77 M |
$10.93 M |
$13.36 M |
$11.39 M |
$126,955.00 |
$212,328.00 |
$107,680.00 |
$0.00 |
Cost of Revenue |
$8.44 M
|
$9.67 M
|
$11.17 M
|
$9.67 M
|
$71,067.00
|
$183,563.00
|
$28,871.00
|
$0.00
|
Gross Profit |
$1.33 M
|
$1.26 M
|
$2.19 M
|
$1.72 M
|
$55,888.00
|
$28,765.00
|
$78,809.00
|
$0.00
|
Gross Profit Ratio |
0.14
|
0.12
|
0.16
|
0.15
|
0.44
|
0.14
|
0.73
|
0
|
Research and Development Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
General & Administrative Expenses |
$4.41 M
|
$1.73 M
|
$1.20 M
|
$1.33 M
|
$356,641.00
|
$241,930.00
|
$0.00
|
$0.00
|
Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General & Administrative Expenses |
$4.41 M
|
$1.73 M
|
$1.20 M
|
$1.33 M
|
$356,641.00
|
$241,930.00
|
$206,715.00
|
$835.00
|
Other Expenses |
-$486,036.00
|
-$179,283.00
|
-$66,491.00
|
-$886,942.00
|
-$25,048.00
|
$273,066.00
|
$0.00
|
$0.00
|
Operating Expenses |
$3.92 M
|
$1.55 M
|
$1.14 M
|
$446,001.00
|
$331,593.00
|
-$31,136.00
|
$206,715.00
|
$835.00
|
Cost And Expenses |
$12.36 M
|
$11.22 M
|
$12.31 M
|
$10.12 M
|
$402,660.00
|
$152,427.00
|
$235,586.00
|
$835.00
|
Interest Income |
$0.00
|
$12,479.00
|
$12,973.00
|
$11,313.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Interest Expense |
$13,929.00
|
$12,479.00
|
$12,973.00
|
$11,313.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Depreciation & Amortization |
$108,423.00
|
$105,419.00
|
$108,215.00
|
$101,603.00
|
$53,332.00
|
$40,611.00
|
$15,031.00
|
$835.00
|
EBITDA |
-$2.49 M |
-$185,761.00 |
$1.16 M |
$1.38 M |
-$222,373.00 |
$100,512.00 |
-$104,383.00 |
$0.00 |
EBITDA Ratio |
-0.25
|
-0.02
|
0.09
|
0.12
|
-1.75
|
0.47
|
-1.05
|
0
|
Operating Income Ratio |
-0.27
|
-0.03
|
0.08
|
0.11
|
-2.17
|
0.28
|
-1.19
|
0
|
Total Other Income/Expenses Net |
-$13,929.00
|
-$12,479.00
|
-$12,973.00
|
-$11,313.00
|
$0.00
|
$0.00
|
$0.00
|
$5.00
|
Income Before Tax |
-$2.61 M
|
-$303,656.00
|
$1.04 M
|
$1.26 M
|
-$275,705.00
|
$59,901.00
|
-$119,414.00
|
-$835.00
|
Income Before Tax Ratio |
-0.27
|
-0.03
|
0.08
|
0.11
|
-2.17
|
0.28
|
-1.11
|
0
|
Income Tax Expense |
$21,526.00
|
$52,310.00
|
$291,283.00
|
$168,411.00
|
-$29,236.00
|
$33,447.00
|
$4,336.00
|
-$835.00
|
Net Income |
-$2.63 M
|
-$355,966.00
|
$751,571.00
|
$1.09 M
|
-$246,469.00
|
$26,454.00
|
-$123,750.00
|
-$835.00
|
Net Income Ratio |
-0.27
|
-0.03
|
0.06
|
0.1
|
-1.94
|
0.12
|
-1.15
|
0
|
EPS |
-0.17 |
-0.0247 |
0.0527 |
0.13 |
-0.0342 |
0.0048 |
-0.0199 |
-0.0001 |
EPS Diluted |
-0.17 |
-0.0247 |
0.0527 |
0.13 |
-0.0342 |
0.0048 |
-0.0199 |
-0.0001 |
Weighted Average Shares Out |
$15.88 M
|
$14.41 M
|
$14.27 M
|
$8.58 M
|
$7.20 M
|
$5.53 M
|
$6.22 M
|
$6.22 M
|
Weighted Average Shares Out Diluted |
$15.88 M
|
$14.41 M
|
$14.27 M
|
$8.58 M
|
$7.20 M
|
$5.53 M
|
$6.22 M
|
$6.22 M
|
Link |
|
|
|
|
|
|
|
|